GENSIGHT BIOLOGICS S.A. (EPA:SIGHT) | WebDisclosure

Basculer en Français

8296	Companies
114899	Keywords
55320	Articles
62454	Press releases

Headlines Articles Press releases GENSIGHT BIOLOGICS S.A.

Home
Companies
GENSIGHT BIOLOGICS S.A.

PRESS RELEASE

published on 10/24/2024 at 21:08, 27 days 16 hours ago

Informations privilégiées / Communiqué sur comptes, résultats
GenSight Biologics publie sa trésorerie au 30 septembre 2024 et fait un point sur ses activités, notamment le succès des tests du LUMEVOQ et les discussions pour assurer le financement. La trésorerie est de 3,4 millions d'euros

Financement Trésorerie GenSight Biologics LUMEVOQ Tests De Contrôle
PRESS RELEASE

published on 10/24/2024 at 21:08, 27 days 16 hours ago

Inside Information / News release on accounts, results
GenSight Biologics reports €3.4 million cash position as of September 30, 2024, updates on LUMEVOQ® drug product status, and financial discussions for future funding

Cash Position Financial Update GenSight Biologics LUMEVOQ AAC Resumption
BRIEF

published on 10/17/2024 at 07:35, 1 month 4 days ago

GenSight Biologics Presents LUMEVOQ® Data at AAO 2024

Gene Therapy GenSight Biologics LUMEVOQ® LHON AAO 2024
BRIEF

published on 10/17/2024 at 07:35, 1 month 4 days ago

GenSight Biologics présente les données de LUMEVOQ® à l'AAO 2024

Thérapie Génique GenSight Biologics LUMEVOQ® LHON AAO 2024
PRESS RELEASE

published on 10/17/2024 at 07:30, 1 month 4 days ago

Inside Information / Other news releases
GenSight Biologics to present scientific updates on LUMEVOQ® gene therapy at AAO 2024, including real-world experience and long-term outcomes for LHON patients

Gene Therapy GenSight Biologics LHON LUMEVOQ AAO 2024
PRESS RELEASE

published on 09/27/2024 at 11:24, 1 month 24 days ago

HALF-YEAR_FINANCIAL_REPORT_JUNE_2024
BRIEF

published on 09/23/2024 at 19:41, 1 month 27 days ago

GenSight Biologics Reports Interim Financial Results for H1 2024

Financial Results Cash Management LUMEVOQ® Early Access Program R&D Expenses
BRIEF

published on 09/23/2024 at 19:41, 1 month 27 days ago

GenSight Biologics publie ses résultats financiers intermédiaires pour le premier semestre 2024

Résultats Financiers LUMEVOQ® Programme D'accès Anticipé Dépenses De Recherche Et Développement Gestion De Trésorerie
PRESS RELEASE

published on 09/23/2024 at 19:36, 1 month 27 days ago

Informations privilégiées / Communiqué sur comptes, résultats
GenSight Biologics publie ses résultats financiers du premier semestre 2024 avec une réduction des dépenses opérationnelles de 60% et l'extension de son horizon de trésorerie. Nouveau Directeur Administratif et Financier nommé

Résultats Financiers GenSight Biologics Directeur Administratif Et Financier Dépenses Opérationnelles Horizon De Trésorerie
PRESS RELEASE

published on 09/23/2024 at 19:36, 1 month 27 days ago

Inside Information / News release on accounts, results
GenSight Biologics reports interim financial results for the first half of 2024, highlighting optimized cash management, extension of cash runway, and upcoming LUMEVOQ® drug product release

Cash Management GenSight Biologics Interim Financial Results LUMEVOQ® Drug Product Release

Accesswire

Published on 11/21/2024 at 13:00, 24 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 24 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 24 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 24 minutes ago

Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 24 minutes ago

Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 9 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 49 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 9 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 17 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 24 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 26 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 26 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 26 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 17 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 18 hours 4 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE